These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37428078)

  • 1. An in-silico investigation based on molecular simulations of novel and potential brain-penetrant GluN2B NMDA receptor antagonists as anti-stroke therapeutic agents.
    El Fadili M; Er-Rajy M; Ali Eltayb W; Kara M; Imtara H; Zarougui S; Al-Hoshani N; Hamadi A; Elhallaoui M
    J Biomol Struct Dyn; 2024 Aug; 42(12):6174-6188. PubMed ID: 37428078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deconstruction - Reconstruction: Analysis of the Crucial Structural Elements of GluN2B-Selective, Negative Allosteric NMDA Receptor Modulators with 3-Benzazepine Scaffold.
    Ritter N; Korff M; Markus A; Schepmann D; Seebohm G; Schreiber JA; Wünsch B
    Cell Physiol Biochem; 2021 Mar; 55(S3):1-13. PubMed ID: 33656308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel brain-penetrant GluN2B NMDAR antagonists via pharmacophore-merging strategy as anti-stroke therapeutic agents.
    Xu Q; Hu M; Li J; Ma X; Chu Z; Zhu Q; Zhang Y; Zhu P; Huang Y; He G
    Eur J Med Chem; 2022 Jan; 227():113876. PubMed ID: 34710748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring neuroprotective potential of Withania somnifera phytochemicals by inhibition of GluN2B-containing NMDA receptors: An in silico study.
    Kumar G; Patnaik R
    Med Hypotheses; 2016 Jul; 92():35-43. PubMed ID: 27241252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the overlapping binding sites of ifenprodil and EVT-101 in GluN2B-containing NMDA receptors using novel chicken embryo forebrain cultures and molecular modeling.
    Fjelldal MF; Freyd T; Evenseth LM; Sylte I; Ring A; Paulsen RE
    Pharmacol Res Perspect; 2019 Jun; 7(3):e00480. PubMed ID: 31164987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying potential GluN2B subunit containing N-Methyl-D-aspartate receptor inhibitors: an integrative
    Singh R; Ganeshpurkar A; Kumar D; Kumar D; Kumar A; Singh SK
    J Biomol Struct Dyn; 2020 Jun; 38(9):2533-2545. PubMed ID: 31232189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational investigation of phytochemicals from
    Ahmad I; Kumar D; Patel H
    J Biomol Struct Dyn; 2022 Oct; 40(17):7991-8003. PubMed ID: 33970806
    [No Abstract]   [Full Text] [Related]  

  • 8. A Novel Binding Mode Reveals Two Distinct Classes of NMDA Receptor GluN2B-selective Antagonists.
    Stroebel D; Buhl DL; Knafels JD; Chanda PK; Green M; Sciabola S; Mony L; Paoletti P; Pandit J
    Mol Pharmacol; 2016 May; 89(5):541-51. PubMed ID: 26912815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subunit arrangement and phenylethanolamine binding in GluN1/GluN2B NMDA receptors.
    Karakas E; Simorowski N; Furukawa H
    Nature; 2011 Jun; 475(7355):249-53. PubMed ID: 21677647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational investigation of the antagonism effect towards GluN2B-Containing NMDA receptor: Combined ligand-based and target-based approach.
    Ma C; Hu B; Zhang L; Zhao Y; Wang M; Wang J; Cheng M
    J Mol Graph Model; 2019 Jan; 86():95-105. PubMed ID: 30343207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying potential inhibitors of C-X-C motif chemokine ligand10 against vitiligo: structure-based virtual screening, molecular dynamics simulation, and principal component analysis.
    Khan MKA; Alouffi S; Ahmad S
    J Biomol Struct Dyn; 2024 Sep; 42(15):8045-8062. PubMed ID: 37565326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A common mechanism allows selective targeting of GluN2B subunit-containing
    Schreiber JA; Schepmann D; Frehland B; Thum S; Datunashvili M; Budde T; Hollmann M; Strutz-Seebohm N; Wünsch B; Seebohm G
    Commun Biol; 2019; 2():420. PubMed ID: 31754650
    [No Abstract]   [Full Text] [Related]  

  • 13. Exploration of the potential neuroprotective compounds targeting GluN1-GluN2B NMDA receptors.
    He M; Wang Y; Zhang X; Zhang L
    J Biomol Struct Dyn; 2023 Dec; 41(20):10900-10908. PubMed ID: 36591642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis of subunit selectivity for competitive NMDA receptor antagonists with preference for GluN2A over GluN2B subunits.
    Lind GE; Mou TC; Tamborini L; Pomper MG; De Micheli C; Conti P; Pinto A; Hansen KB
    Proc Natl Acad Sci U S A; 2017 Aug; 114(33):E6942-E6951. PubMed ID: 28760974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nobiletin as a Neuroprotectant against NMDA Receptors: An In Silico Approach.
    Jahan S; Redhu NS; Siddiqui AJ; Iqbal D; Khan J; Banawas S; Alaidarous M; Alshehri B; Mir SA; Adnan M; Pant AB
    Pharmaceutics; 2022 May; 14(6):. PubMed ID: 35745697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular docking and molecular dynamics approach to identify potential compounds in
    Tung BT; Hang TTT; Kim NB; Nhung NH; Linh VK; Thu DK
    J Complement Integr Med; 2022 Dec; 19(4):955-965. PubMed ID: 35621378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The discovery of subunit-selective GluN1/GluN2B NMDAR antagonist via pharmacophere-based virtual screening.
    Tang J; Jin J; Huang Z; An F; Huang C; Jiang W
    Exp Biol Med (Maywood); 2023 Dec; 248(24):2560-2577. PubMed ID: 38282535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-Methyltetrahydro-3-benzazepin-1-ols - The missing link in SAR of GluN2B selective NMDA receptor antagonists.
    Dey S; Schepmann D; Wünsch B
    Bioorg Med Chem; 2018 Jan; 26(2):501-508. PubMed ID: 29254894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping the high-affinity binding domain of 5-substituted benzimidazoles to the proximal N-terminus of the GluN2B subunit of the NMDA receptor.
    Wee XK; Ng KS; Leung HW; Cheong YP; Kong KH; Ng FM; Soh W; Lam Y; Low CM
    Br J Pharmacol; 2010 Jan; 159(2):449-61. PubMed ID: 20082612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repurposing of cefpodoxime proxetil as potent neuroprotective agent through computational prediction and in vitro validation.
    Quan J; Ma C; Wang Y; Hu B; Zhang D; Zhang Z; Wang J; Cheng M
    J Biomol Struct Dyn; 2021 Jul; 39(11):3975-3985. PubMed ID: 32448083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.